News

GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo

GlycoT

BALTIMORE, Sept. 14, 2020 /PRNewswire/ — GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.daiichisankyo.com). The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB […]

Comments Off on GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo Continue Reading →

BioBuzz: MaxCyte Appoints Amanda L. Murphy as CFO, Names Ron Holtz as SVP & CAO

Maxcyte logo square

Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectorsHoltz to remain on the Board of Directors of the Company and retain key elements of his executive role, including overseeing accounting, budgeting, and supporting key business operations Gaithersburg, Maryland – September 9, 2020: — MaxCyte, […]

Comments Off on BioBuzz: MaxCyte Appoints Amanda L. Murphy as CFO, Names Ron Holtz as SVP & CAO Continue Reading →

Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19

Cartesian Logo New JPG

Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS. Gaithersburg, MD, September 1, 2020 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer, autoimmune diseases and respiratory diseases, today announced that it has initiated […]

Comments Off on Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19 Continue Reading →

Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic

lifescileader

Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic. Appearing in this video are: Jeremy Levin, DPhil, MB, BChir, CEO of Ovid TherapeuticsGil Van Bokkelen, Ph.D., chairman and CEO of AthersysRachel King, CEO, GlycoMimeticsTed Love, M.D., President […]

Comments Off on Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic Continue Reading →

BBJ: UMB startup company’s exclusive licensed tool supports health care professionals

pumasjpg

By Jamie Lacey-Moreira – For the University of Maryland, Baltimore (UMB)A company spun out of the University of Maryland School of Pharmacy aims to leverage its approach — combining modern artificial intelligence (AI) with traditional mechanistic models — to arm health care professionals with the best data to provide personalized treatment trajectories for patients. Pumas-Al, […]

Comments Off on BBJ: UMB startup company’s exclusive licensed tool supports health care professionals Continue Reading →

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

MAXCYTE-New-Logo-2016-LARGE

APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials VIENNA, AUSTRIA and GAITHERSBURG, MD, July 8, 2020 APEIRON Biologics AG (“APEIRON”), a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases, and MaxCyte, Inc., a […]

Comments Off on APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401 Continue Reading →

Protaryx Medical Announces $8.3M in Funding for First-in-Class Technology for Left Atrial Access in Transcatheter Cardiac Procedures

Protaryx

$5.1M Series A Funding Led by Ajax Health Will Be Used to Develop First-in-Class Product Designed with Three-Dimensional, Independent Steerability to Deliver Reliable Access BALTIMORE–(BUSINESS WIRE)–Protaryx™ Medical, a company committed to reimagining access to the left atrium for transcatheter cardiac procedures, today announced that it has raised $8.3 million in funding to develop the company’s […]

Comments Off on Protaryx Medical Announces $8.3M in Funding for First-in-Class Technology for Left Atrial Access in Transcatheter Cardiac Procedures Continue Reading →

BioBuzz: Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond

BioBuzzLogo

In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and not hit somebody who worked at MedImmune”. This statement emphasizes how important the company was in seeding the growth of the biotech industry in Maryland. Founded by Wayne T. Hockmeyer in 1988 as Molecular Vaccines, Inc., […]

Comments Off on BioBuzz: Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond Continue Reading →

UMB Startup Breethe Acquired by Abiomed to Commercialize Wearable Artificial Lung System

BreetheNew

The Deal Marks Another Successful Exit Supported by UM Ventures Breethe, a company built on technology licensed out of the University of Maryland, Baltimore (UMB), was acquired by Abiomed, a publicly-traded medical device company located in Massachusetts, in late April 2020. Financials were not disclosed, but the deal represents another UMB success story that received early backing […]

Comments Off on UMB Startup Breethe Acquired by Abiomed to Commercialize Wearable Artificial Lung System Continue Reading →

MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

Maxcyte logo square

Gaithersburg, Maryland – May 18, 2020: – MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology’s (ASCO) upcoming annual meeting. […]

Comments Off on MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting Continue Reading →